- Home
- OVLY vs AARD Comparison
OVLY vs AARD Comparison
Compare OVLY & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVLY
- AARD
- Stock Information
- Founded
- OVLY 1990
- AARD 2017
- Country
- OVLY United States
- AARD United States
- Employees
- OVLY N/A
- AARD N/A
- Industry
- OVLY Major Banks
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- OVLY Finance
- AARD Health Care
- Exchange
- OVLY Nasdaq
- AARD Nasdaq
- Market Cap
- OVLY 219.0M
- AARD 231.9M
- IPO Year
- OVLY N/A
- AARD 2025
- Fundamental
- Price
- OVLY $28.20
- AARD $10.33
- Analyst Decision
- OVLY
- AARD Strong Buy
- Analyst Count
- OVLY 0
- AARD 8
- Target Price
- OVLY N/A
- AARD $30.63
- AVG Volume (30 Days)
- OVLY 8.4K
- AARD 165.3K
- Earning Date
- OVLY 10-22-2025
- AARD 11-13-2025
- Dividend Yield
- OVLY 2.08%
- AARD N/A
- EPS Growth
- OVLY N/A
- AARD N/A
- EPS
- OVLY 2.84
- AARD N/A
- Revenue
- OVLY $79,783,000.00
- AARD N/A
- Revenue This Year
- OVLY N/A
- AARD N/A
- Revenue Next Year
- OVLY N/A
- AARD N/A
- P/E Ratio
- OVLY $10.13
- AARD N/A
- Revenue Growth
- OVLY 2.98
- AARD N/A
- 52 Week Low
- OVLY $22.70
- AARD $4.88
- 52 Week High
- OVLY $32.24
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- OVLY 53.18
- AARD 43.11
- Support Level
- OVLY $28.24
- AARD $9.75
- Resistance Level
- OVLY $30.05
- AARD $11.51
- Average True Range (ATR)
- OVLY 0.60
- AARD 0.84
- MACD
- OVLY 0.14
- AARD 0.01
- Stochastic Oscillator
- OVLY 48.32
- AARD 37.64
About OVLY Oak Valley Bancorp (CA)
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.